N/A
N=706
Log2Lose: Incenting Weight Loss and Dietary Self-monitoring in Real-time to Improve Weight Management Among Adults With Obesity
Obesity
Bottom Line
View on ClinicalTrials.gov: NCT04770909 ↗Enrolled (actual)
706
Serious AEs
5.4%
Results posted
May 2026
Primary outcome: Primary: Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 26 Weeks — 40; 43; 48; 32 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Incentives for dietary self-monitoring and weight loss (Behavioral); Incentives for dietary self-monitoring (Behavioral); Incentives for weight loss (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Wisconsin, Madison
- Primary completion
- Apr 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 26 Weeks |
40; 43; 48; 32 | — |
| SECONDARY Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 52 Weeks |
48; 47; 53; 41 | — |
| SECONDARY Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 78 Weeks |
47; 48; 44; 41 | — |
| SECONDARY Change in Use of Cardiovascular Medications From Baseline to 78 Weeks for All Participants |
22; 38; 26; 26; 18; 16 | — |
| SECONDARY Change in Use of Cardiovascular Medications From Participants Who Took 1 or More Medications From Baseline to 78 Weeks |
22; 38; 26; 26; 18; 16 | — |
| SECONDARY Diastolic Blood Pressure |
81.31; 81.31; 81.31; 81.31; 79.40; 81.13 | — |
| SECONDARY Systolic Blood Pressure |
124.48; 124.48; 124.48; 124.48; 123.56; 126.02 | — |
Summary
This study involves an evaluation of whether providing small incentives weekly for dietary self-monitoring and/or weight loss improves short- and long-term weight loss. Participants can expect to be on study for 18 months.
Eligibility Criteria
Inclusion Criteria
- BMI ≥30 kg/m2
- Desire to lose weight
- Agrees to attend outcome visits per protocol
- Available for class times
- Transportation and ability to attend in-person study visits at baseline (screening), 26, 52, and 78 weeks
- Able to stand for weight measurements without assistance
- Able to speak and read English
- Able to download and use the MyFitnessPal and Fitbit apps daily
- Possess smart phone with data and texting plan
- Have or willing to create a Gmail address
- Able to connect to a video conference call using a smartphone, tablet or computer with a webcam and microphone
- Score of at least 4 out of 6 on a validated cognitive screener
Exclusion Criteria
- Weight >380 lb
- Weight loss of at least 10 lbs in the month prior to screening
- Currently enrolled or enrolled in previous month in a clinical, research, or community program focusing on lifestyle change that could affect weight
- Current use of weight loss medication
- History of bariatric surgery or planning to have bariatric surgery in the study timeframe
- Residing in a nursing home or receiving home health care
- Impaired hearing
- Significant dementia, drug or alcohol misuse, or unstable psychiatric illness (e.g., schizophrenia, psychosis)
- Current treatment for cancer or being treated for cancer (besides basal cell carcinoma or squamous cell) in the last 6 months
- Use of insulin, sulfonylureas, or meglitinides due to increased risk for hypoglycemia
- Pregnant, breastfeeding, or planning to become pregnant within the study timeframe
- Diuretic medication doses higher than hydrochlorothiazide 25 mg daily, furosemide 40 mg daily, torsemide 20 mg daily, bumetanide 1 mg daily, or any use of metolazone; use of potassium-sparing diuretics is acceptable
- Chronic kidney disease at stage 4 or 5
- Unstable heart disease in the 6 months prior to screening
- Exertional chest pain
- History of ascites requiring paracentesis
- Pain, fainting or other conditions that prohibit mild/moderate exercise
Data sourced from ClinicalTrials.gov (NCT04770909). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.